These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 15260819

  • 21. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [Abstract] [Full Text] [Related]

  • 22. Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay.
    Casonato A, Fabris F, Pontara E, Cattini MG, Zocca N, Gallinaro L, Girolami A, Pagnan A.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):296-304. PubMed ID: 16959682
    [Abstract] [Full Text] [Related]

  • 23. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Jul; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 24. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
    Tauber H, Ott H, Streif W, Weigel G, Loacker L, Fritz J, Heinz A, Velik-Salchner C.
    Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
    [Abstract] [Full Text] [Related]

  • 25. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 26. von Willebrand factor standards for plasma and concentrate testing.
    Hubbard AR.
    Semin Thromb Hemost; 2006 Jul; 32(5):522-8. PubMed ID: 16862526
    [Abstract] [Full Text] [Related]

  • 27. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F.
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [Abstract] [Full Text] [Related]

  • 28. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U, Drewke E.
    Beitr Infusionsther Transfusionsmed; 1994 Jan; 32():408-14. PubMed ID: 9422121
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
    Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U.
    J Thromb Haemost; 2008 Apr; 6(4):569-76. PubMed ID: 18208537
    [Abstract] [Full Text] [Related]

  • 30. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ, Kershaw G, McLachlan AJ, Lloyd J.
    Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
    [Abstract] [Full Text] [Related]

  • 31. Alterations in von Willebrand factor antigen in premature infants with respiratory distress syndrome and chronic lung disease.
    Patrick CH, Lazarchick J, Horn BS.
    Ann Clin Lab Sci; 1993 Nov; 23(1):39-46. PubMed ID: 8430999
    [Abstract] [Full Text] [Related]

  • 32. Von Willebrand factor in Italian centenarians.
    Coppola R, Mari D, Lattuada A, Franceschi C.
    Haematologica; 2003 Jan; 88(1):39-43. PubMed ID: 12551825
    [Abstract] [Full Text] [Related]

  • 33. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A.
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [Abstract] [Full Text] [Related]

  • 34. Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura.
    Casonato A, Pontara E, Bertomoro A, Ossi E, Vincenti M, Girolami A, Borsatti A, Bertaglia G.
    Am J Hematol; 1996 Jan; 51(1):7-11. PubMed ID: 8571941
    [Abstract] [Full Text] [Related]

  • 35. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 36. Influence of ABO blood group on von Willebrand factor tests in healthy Saudi blood donors.
    Alharbi A, Hassan SB, Al-Momen AK, Al-Saleh K, Nasr R, Kohgear H, Owaidah T.
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):211-215. PubMed ID: 29369083
    [Abstract] [Full Text] [Related]

  • 37. Autosomal dominant von Willebrand disease type 2M.
    Hermans C, Batlle J.
    Acta Haematol; 2009 Mar; 121(2-3):139-44. PubMed ID: 19506360
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of an automated platelet-based assay of ristocetin cofactor activity.
    Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F.
    Haemophilia; 2011 Mar; 17(2):252-6. PubMed ID: 21070498
    [Abstract] [Full Text] [Related]

  • 39. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW.
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.